SCHEMBL4885958

SCHEMBL4885958

O=C(N/N=C(\C=N\O)c1ccccc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
KMT2A Q03164 4/20 0.54
KDM4E B2RXH2 3/20 0.54
POLB P06746 3/20 0.54
PTBP1 P26599 2/20 0.54
HTT P42858 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
KCNK3 O14649 1/20 0.52
MAPT P10636 5/20 0.52
MEN1 O00255 3/20 0.49
KAT6A Q92794 1/20 0.49
GAA P10253 2/20 0.48
HSP90AA1 P07900 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48
ALDH1A1 P00352 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4885965 1.00 LMNA (0.54) LMNAKMT2AKDM4EPOLBPTBP1
SCHEMBL4885748 0.91 P2RX1 (0.48) LMNAKMT2AKDM4EPOLBPTBP1
SCHEMBL4885991 0.90 KCNK3 (0.47) LMNAKMT2AKDM4EPOLBPTBP1
SCHEMBL4885989 0.90 KCNK3 (0.47) LMNAKMT2AKDM4EPOLBPTBP1
SCHEMBL4883201 0.88 RAB9A (0.49) LMNAKMT2AKDM4EPOLBSMN1; SMN2
SCHEMBL4883196 0.88 RAB9A (0.49) LMNAKMT2AKDM4EPOLBSMN1; SMN2
SCHEMBL4877981 0.88 MAPT (0.48) LMNAKMT2AKDM4EPOLBPTBP1
SCHEMBL4882188 0.88 MAPT (0.48) LMNAKMT2AKDM4EPOLBPTBP1
SCHEMBL4877985 0.88 MAPT (0.48) LMNAKMT2AKDM4EPOLBPTBP1
SCHEMBL4882184 0.88 MAPT (0.48) LMNAKMT2AKDM4EPOLBPTBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 LMNA 2096/4885KMT2A 3684/4885KDM4E 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.